Three-year Active Surveillance Outcomes in a Contemporary Community Urology Cohort in the United States.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 18 10 2018
revised: 08 04 2019
accepted: 15 04 2019
pubmed: 29 4 2019
medline: 16 1 2020
entrez: 29 4 2019
Statut: ppublish

Résumé

To determine the 3-year outcomes of men with prostate cancer managed with active surveillance (AS) in a cohort of geographically diverse community-based urology practices. AS is the management of choice for a majority of men with lower risk prostate cancer. Five hundred and forty-eight men on AS were followed for a median of 3.35 years. 89% (492) continued to follow-up with diagnosing practice. 32% (171) discontinued AS. On multivariate analysis, increasing NCCN risk classification (Hazard ratio [HR] 1.65, P = 0.02 and HR 2.09, P < 0.01 for low and intermediate risk vs very low risk) was significantly associated with discontinuation. Among those who discontinued AS, surgery and radiation were utilized equally (47% and 53%, respectively, P = 0.48). In this community-based cohort of men on AS, a minority was lost to follow-up and adherence to AS was similar to other reports. Disease characteristics more than sociodemographic characteristics correlated with adherence to AS, while surgery and radiotherapy were utilized equally among those discontinuing AS, both suggesting guideline concordant practice of medicine.

Identifiants

pubmed: 31029668
pii: S0090-4295(19)30371-1
doi: 10.1016/j.urology.2019.04.017
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

72-78

Informations de copyright

Published by Elsevier Inc.

Auteurs

Jeremy B Shelton (JB)

UCLA, Urology, 17003 Wilshire Blvd, Los Angeles, CA91436, United States. Electronic address: jshelton@mednet.ucla.edu.

Thomas A Paivanas (TA)

CUSP Clinical Research Consortium. Electronic address: Tom@cuspgroup.net.

Phil Buffington (P)

The Urology Group. Electronic address: PBuffington@urologygroup.com.

Stephen R Ruyle (SR)

The Urology Center of Colorado. Electronic address: sruyle@tucc.com.

Edward S Cohen (ES)

Genesis Healthcare Partners. Electronic address: ecohen@genhp.com.

Richard Natale (R)

Carolina Urology Partners. Electronic address: Richard.Natale@carolinaurologypartners.com.

Bryan Mehlhaff (B)

Oregon Urology Institute. Electronic address: bmehlhaff@comcast.net.

Ronald Suh (R)

Urology of Indiana. Electronic address: rsuh@urologyin.com.

Timothy J Bradford (TJ)

Virginia Urology. Electronic address: tbradford@uro.com.

Alec S Koo (AS)

Skyline Urology. Electronic address: alec.koo@skyuro.com.

Lorna Kwan (L)

UCLA, Urology, 17003 Wilshire Blvd, Los Angeles, CA91436, United States. Electronic address: lornakwanherbert@gmail.com.

Neal Shore (N)

Atlantic Urology Clinics. Electronic address: nshore@gsuro.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH